Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.
Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, Wagner CB, Kocoglu MH, Rapoport A, Atrash S, Voorhees PM, Khouri J, Dima D, Afrough A, Kaur G, Anderson LD Jr, Simmons G, Davis JA, Kalariya N, Peres LC, Lin Y, Janakiram M, Nadeem O, Alsina M, Locke FL, Sidana S, Hansen DK, Patel KK, Castaneda Puglianini OA. Ferreri CJ, et al. Among authors: patel kk. Blood Cancer J. 2023 Aug 9;13(1):117. doi: 10.1038/s41408-023-00886-8. Blood Cancer J. 2023. PMID: 37558706 Free PMC article.
Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma.
Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Veltri LW, et al. Cancer. 2017 Sep 15;123(18):3568-3575. doi: 10.1002/cncr.30770. Epub 2017 May 17. Cancer. 2017. PMID: 28513828 Free PMC article.
A phase 1 study of filanesib, carfilzomib, and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Lee HC, Shah JJ, Feng L, Manasanch EE, Lu R, Morphey A, Crumpton B, Patel KK, Wang ML, Alexanian R, Thomas SK, Weber DM, Orlowski RZ. Lee HC, et al. Among authors: patel kk. Blood Cancer J. 2019 Oct 1;9(10):80. doi: 10.1038/s41408-019-0240-6. Blood Cancer J. 2019. PMID: 31575851 Free PMC article. Clinical Trial. No abstract available.
Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Afrough A, et al. Among authors: patel kk. Transplant Cell Ther. 2022 Jun;28(6):307.e1-307.e8. doi: 10.1016/j.jtct.2022.03.020. Epub 2022 Mar 22. Transplant Cell Ther. 2022. PMID: 35331973 Free article.
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma.
Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Afrough A, et al. Among authors: patel kk. Transplant Cell Ther. 2023 Apr;29(4):264.e1-264.e9. doi: 10.1016/j.jtct.2022.05.023. Epub 2022 May 20. Transplant Cell Ther. 2023. PMID: 35605883 Free article.
Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium.
Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, Gonzalez R, Sborov DW, Wagner C, Dima D, Hashmi H, Kocoglu MH, Atrash S, Simmons G, Kalariya N, Ferreri C, Afrough A, Kansagra A, Voorhees P, Baz R, Khouri J, Alsina M, McGuirk J, Locke FL, Patel KK. Hansen DK, et al. Among authors: patel kk. J Clin Oncol. 2023 Apr 10;41(11):2087-2097. doi: 10.1200/JCO.22.01365. Epub 2023 Jan 9. J Clin Oncol. 2023. PMID: 36623248 Free PMC article.
Ethical Challenges with Multiple Myeloma BCMA Chimeric Antigen Receptor T Cell Slot Allocation: A Multi-Institution Experience.
Kourelis T, Bansal R, Berdeja J, Siegel D, Patel K, Mailankody S, Htut M, Shah N, Wong SW, Sidana S, Cowan AJ, Alsina M, Cohen A, Holstein SA, Bergsagel L, Ailawadhi S, Raje N, Dhakal B, Rossi A, Lin Y. Kourelis T, et al. Transplant Cell Ther. 2023 Apr;29(4):255-258. doi: 10.1016/j.jtct.2023.01.012. Epub 2023 Jan 18. Transplant Cell Ther. 2023. PMID: 36681151 Free PMC article.
Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients.
Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Pasvolsky O, et al. Among authors: patel kk. Blood Cancer J. 2023 May 3;13(1):68. doi: 10.1038/s41408-023-00842-6. Blood Cancer J. 2023. PMID: 37137874 Free PMC article.
Reply to R. Chakraborty et al.
Hansen DK, Sidana S, Peres LC, Patel KK. Hansen DK, et al. Among authors: patel kk. J Clin Oncol. 2023 Jul 10;41(20):3658-3659. doi: 10.1200/JCO.23.00568. Epub 2023 May 26. J Clin Oncol. 2023. PMID: 37235841 No abstract available.
333 results